Expression of p53 and beta-catenin proteins in hepatocellular carcinoma

Authors

  • Enkhtuya Ariya Laboratory of Molecular Biology, Institute of Biology, Mongolian Academy of Sciences, Ulaanbaatar, Mongolia https://orcid.org/0000-0002-2623-840X
  • Buyanbat Khurelsukh Laboratory of Molecular Biology, Institute of Biology, Mongolian Academy of Sciences, Ulaanbaatar, Mongolia https://orcid.org/0000-0003-2441-6118
  • Ganbat Sondor Laboratory of Molecular Biology, Institute of Biology, Mongolian Academy of Sciences, Ulaanbaatar, Mongolia https://orcid.org/0000-0002-6834-6396
  • Enkhbaatar Ankhbayar Department of General Surgery, Second State Central Hospital, Ulaanbaatar, Mongolia
  • Baatarjav Gan-Erdene Department of General Surgery, Second State Central Hospital, Ulaanbaatar, Mongolia
  • Nanzaddorj Taivan Department of General Surgery, Second State Central Hospital, Ulaanbaatar, Mongolia
  • Davaakhuu Gantulga Laboratory of Molecular Biology, Institute of Biology, Mongolian Academy of Sciences, Ulaanbaatar, Mongolia https://orcid.org/0000-0003-3792-7101
  • Tsendsuren Oyunsuren Laboratory of Molecular Biology, Institute of Biology, Mongolian Academy of Sciences, Ulaanbaatar, Mongolia https://orcid.org/0000-0001-9906-2428

DOI:

https://doi.org/10.5564/pib.v38i1.2545

Keywords:

mutation, tumor, western blot

Abstract

The expression of p53 and beta-catenin proteins in hepatocellular carcinoma (HCC) samples with mutations in the tumor suppressor TP53 gene, which has a high frequency of mutations in liver cancer, and the CTNNB1 gene, which plays an important role in the Wnt signaling pathway, were identified. As a result, the beta-catenin protein was increased in 83.33% of liver tumor samples with CTNNB1 gene mutation, and p53 protein expression was increased in 50% of samples with TP53 gene mutation. According to this, it may be that liver tumors were caused by changes in p53 and beta-catenin protein expression.

Элэгний хорт хавдрын эсийн p53, бета-катенин уургийн экспресс

Элэгний хорт хавдрын мутацийн өндөр давтамжтай тохиолддог хавдар дарангуйлагч ТР53 ген болон Wnt дохиоллын замд чухал үүрэгтэй оролцдог CTNNB1 генийн мутаци илэрсэн элэгний хавдрын дээжүүдэд уургийн (p53, бета катенин) нийлэгжлийг вестерн блотын аргаар судлав. Судалгааны дүнд CTNNB1 генийн мутацитай элэгний хавдрын дээжүүдийн 83.33%-д бета-катенин уураг, ТР53 генийн мутацитай дээжүүдийн 50%-д р53 уургийн нийлэгжил тус тус нэмэгдсэн байв. Үүнээс үзэхэд p53 болон бета-катенин уургийн нийлэгжлийн өөрчлөлтөөр элэгний хавдар үүссэн байх магадлалтай.

Түлхүүр үгс: мутаци, хавдар, вестерн блот

Abstract
131
PDF 111

References

“Liver cancer statistics,” World cancer research fund international, 2020. https://www.wcrf.org/cancer-trends/liver-cancer-statistics/

Ding et al., “Precision medicine for hepatocellular carcinoma: driver mutations and targeted therapy,” Oncotarget, vol. 8, no. 33, pp. 55715–55730, 2017, https://doi.org/10.18632/oncotarget.18382.

Tornesello et al., “Mutations in TP53, CTNNB1 and PIK3CA genes in hepatocellular carcinoma associated with hepatitis B and hepatitis C virus infections,” Genomics, vol. 102, no. 2, pp. 74–83, 2013, https://doi.org/10.1016/j.ygeno.2013.04.001.

MacDonald et al., “Wnt/β-Catenin Signaling: Components, Mechanisms, and Diseases,” Dev. Cell, vol. 17, no. 1, pp. 9–26, 2009, https://doi.org/10.1016/j.devcel.2009.06.016.

Kim et al., “Promotion of growth factor signaling as a critical function of β-catenin during HCC progression,” Nat. Commun., vol. 10, no. 1, p. 1909, 2019, https://doi.org/10.1038/s41467-019-09780-z.

Paek et al., “Cell-to-Cell Variation in p53 Dynamics Leads to Fractional Killing,” Cell, vol. 165, no. 3, pp. 631–642, 2016, https://doi.org/10.1016/j.cell.2016.03.025.

Sano et al., “Disruptive TP53 mutation is associated with aggressive disease characteristics in an orthotopic murine model of oral tongue cancer,” Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res., vol. 17, no. 21, pp. 6658–6670, 2011, https://doi.org/10.1158/1078-0432.CCR-11-0046.

Gao et al., “Exon 3 mutations of CTNNB1 drive tumorigenesis: a review,” Oncotarget, vol. 9, no. 4, pp. 5492–5508, 2017, https://doi.org/10.18632/oncotarget.23695.

Downloads

Published

2021-12-14

How to Cite

[1]
E. Ariya, “Expression of p53 and beta-catenin proteins in hepatocellular carcinoma”, Proc. Inst. Biol., vol. 38, no. 1, pp. 172–179, Dec. 2021.

Issue

Section

Articles

Categories